XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.2
Revenue Recognition (Tables)
6 Months Ended
Jun. 30, 2022
Summary of Disaggregation of Revenues

The following table disaggregates our product revenue, net by product and geographic region and disaggregates our other revenues by geographic region (in thousands):

 

 

 

Three Months Ended

 

 

Three Months Ended

 

 

 

June 30, 2022

 

 

June 30, 2021

 

 

 

U.S.

 

 

Non U.S.

 

 

Total

 

 

U.S.

 

 

Non U.S.

 

 

Total

 

Product revenue, net

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

HEPLISAV-B

 

$

31,739

 

 

$

941

 

 

$

32,680

 

 

$

13,688

 

 

$

-

 

 

$

13,688

 

CpG 1018

 

 

-

 

 

 

222,640

 

 

 

222,640

 

 

 

-

 

 

 

38,989

 

 

 

38,989

 

Total product revenue, net

 

$

31,739

 

 

$

223,581

 

 

$

255,320

 

 

$

13,688

 

 

$

38,989

 

 

$

52,677

 

Other revenue

 

 

1,083

 

 

 

61

 

 

 

1,144

 

 

 

-

 

 

 

90

 

 

 

90

 

Total revenues

 

$

32,822

 

 

$

223,642

 

 

$

256,464

 

 

$

13,688

 

 

$

39,079

 

 

$

52,767

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Six Months Ended

 

 

Six Months Ended

 

 

 

June 30, 2022

 

 

June 30, 2021

 

 

 

U.S.

 

 

Non U.S.

 

 

Total

 

 

U.S.

 

 

Non U.S.

 

 

Total

 

Product revenue, net

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

HEPLISAV-B

 

$

52,549

 

 

$

941

 

 

$

53,490

 

 

$

21,991

 

 

$

-

 

 

$

21,991

 

CpG 1018

 

 

-

 

 

 

314,157

 

 

 

314,157

 

 

 

-

 

 

 

113,571

 

 

 

113,571

 

Total product revenue, net

 

$

52,549

 

 

$

315,098

 

 

$

367,647

 

 

$

21,991

 

 

$

113,571

 

 

$

135,562

 

Other revenue

 

 

2,689

 

 

 

120

 

 

 

2,809

 

 

 

260

 

 

 

280

 

 

 

540

 

Total revenues

 

$

55,238

 

 

$

315,218

 

 

$

370,456

 

 

$

22,251

 

 

$

113,851

 

 

$

136,102

 

Summary of Deferred Revenue The following table summarizes balances and activities in our deferred revenue accounts for the six months ended June 30, 2022 (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at
Beginning
of Period

 

 

Additions (1)

 

 

Subtractions (2)

 

 

Revenue recognized in the current period included in deferred revenue balance at the beginning of the period

 

 

Balance
at End of
Period

 

Six months ended June 30, 2022:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Deferred revenue

 

$

349,864

 

 

$

12,068

 

 

$

(6,534

)

 

$

(163,400

)

 

$

191,998

 

Long-term deferred revenue

 

 

5,385

 

 

 

6,582

 

 

 

(11,967

)

 

 

-

 

 

 

-

 

 

(1)
Additions are primarily payments received or invoices issued before we satisfy our performance obligations.
(2)
Subtractions are primarily revenues recognized in the period included in deferred revenue during the period and reclassification from long-term deferred revenue to accrued liabilities.
HEPLISAV-B  
Schedule of Revenues from Major Customers

The following table summarizes HEPLISAV-B product revenue from each of our three largest Customers (as a percentage of total HEPLISAV-B net product revenue):

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

June 30,

 

 

June 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Largest Customer

 

 

18

%

 

 

28

%

 

 

21

%

 

 

28

%

Second largest Customer

 

 

18

%

 

 

21

%

 

 

18

%

 

 

23

%

Third largest Customer

 

 

18

%

 

 

16

%

 

 

17

%

 

 

17

%

 

Summary of Product Revenue Allowance and Reserve Categories

The following table summarizes balances and activities in HEPLISAV-B product revenue allowance and reserve categories for the six months ended June 30, 2022 (in thousands):

 

 

 

Balance at
Beginning
of Period

 

 

Provisions
related to
current
period sales

 

 

Credit or
payments
made during
the period

 

 

Balance
at End of
Period

 

Six months ended June 30, 2022:

 

 

 

 

 

 

 

 

 

 

 

 

Accounts receivable reserves(1)

 

$

3,823

 

 

$

15,201

 

 

$

(12,602

)

 

$

6,422

 

Revenue reserve accruals(2)

 

 

8,253

 

 

 

10,333

 

 

 

(9,945

)

 

 

8,641

 

 

(1)
Reserves are for chargebacks, discounts and other fees.
(2)
Accruals are for returns, rebates and other fees.
CpG 1018  
Schedule of Revenues from Major Customers

The following table summarizes CpG 1018 product revenue from each of our three largest collaboration partners (as a percentage of total CpG 1018 adjuvant net product revenue):

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

June 30,

 

 

June 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Largest collaboration partner

 

 

41

%

 

 

63

%

 

 

38

%

 

 

79

%

Second largest collaboration partner

 

 

31

%

 

 

27

%

 

 

36

%

 

 

15

%

Third largest collaboration partner

 

 

23

%

 

 

10

%

 

 

22

%

 

 

5

%

Summarizes balances and activities in our contract asset account The following table summarizes balances and activities in our contract asset account (in thousands):

 

 

 

Balance at
Beginning
of Period

 

 

Additions (1)

 

 

Subtractions (2)

 

 

Balance
at End of
Period

 

Six months ended June 30, 2022:

 

 

 

 

 

 

 

 

 

 

 

 

Contract asset

 

$

62,525

 

 

$

12,134

 

 

$

(3,151

)

 

$

71,508

 

(1) Additions are revenues recognized for CpG 1018 adjuvant transferred to Clover that is reserved under the CEPI Agreement, as amended.

(2) Subtractions are reclassifications from contract asset to accounts receivables.